NCE6: Translating Tissue Engineering from Bench Top to Chair Side
Program Track: Tissue Engineering and Hard Tissue Reconstruction
Presenters
.jpg)
Description
Session Overview
This session features two leaders in periodontology and regenerative medicine who will examine the full translation pathway—from discovery to clinical adoption—of recombinant human platelet-derived growth factor (rhPDGF) and other innovative therapies. The program highlights scientific development, regulatory and translational hurdles, real‑world evidence, and the practical drivers of adoption in everyday practice.
Overall Goals of the Session
To explore how regenerative therapies progress from laboratory discovery to routine clinical use, emphasizing the role of robust evidence, patient-reported outcomes, and clinical leadership in successful adoption.
Samuel Lynch, DMSc, DMD
Translating rhPDGF from Discovery to Clinical Adoption and Commercial Success as a Regenerative Medicine Therapeutic
Recombinant pure platelet-derived growth factor (rhPDGF) is the only growth factor approved for periodontal regeneration in North America. It has also been approved for promoting regeneration of bone and skin in orthopedic and dermatologic/plastic surgery indications, respectively, and is now one of the fastest growing regenerative technologies in aesthetic medicine. It is estimated that the application of rhPDGF has enhanced treatment for more than five million patients worldwide. Dr. Lynch will share the story of PDGF discovery and development and highlight the challenges encountered as a translational medicine scientist and entrepreneur.
Educational Objectives:
- Describe current applications of pure PDGF in regenerative medicine.
- Explain the development of pure PDGF as a broad regenerative therapeutic.
- Identify key challenges in translational medicine.
Michael K. McGuire, DDS
Driving Innovative Clinical Therapy Toward Successful Adoption
Successful adoption of innovative clinical therapies requires more than promising early results. Real‑world evidence, meaningful patient outcomes, and long‑term data—supported by respected clinical influencers—are essential to move new treatments from the lab to widespread clinical use. This program explores the critical role of practice‑based research in bridging that gap.
Educational Objectives:
- Explain why alternatives to gold‑standard treatments are rarely adopted in their initial iteration.
- Discuss the growing influence of patient‑reported outcomes on treatment choices compared with objective clinical metrics.
- Recognize the value of real‑world evidence in generating data applicable to everyday clinical practice.
CE Hours: .75
